Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery - An update.

Autor: Jermain SV; Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Ave., A1920, Austin, TX 78712, USA. Electronic address: sjermain15@utexas.edu., Brough C; DisperSol Technologies, LLC, 111 Cooperative Way, Georgetown, TX 78626, USA., Williams RO 3rd; Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Ave., A1920, Austin, TX 78712, USA.
Jazyk: angličtina
Zdroj: International journal of pharmaceutics [Int J Pharm] 2018 Jan 15; Vol. 535 (1-2), pp. 379-392. Date of Electronic Publication: 2017 Nov 08.
DOI: 10.1016/j.ijpharm.2017.10.051
Abstrakt: Poor water-solubility remains a typical property of drug candidates in pharmaceutical development pipelines today. Various processes have been developed to increase the solubility, dissolution rate, and bioavailability of these active ingredients belonging to biopharmaceutical classification system (BCS) II and IV classifications. Since the early 2000s, nanocrystal delivery and amorphous solid dispersions are more established techniques to overcome the limitations of poorly-water soluble drugs in FDA available products. This article provides an updated review of nanocrystal and amorphous solid dispersion techniques primarily for orally delivered medicaments. The thermodynamic and kinetic theories relative to these technologies are presented along with marketed product evaluations and a survey of commercially relevant scientific literature.
(Copyright © 2017 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: